Abstract |
Immunomodulation with cytokines was used to improve the result of high-dose chemotherapy (HDC)/autologous hematopoietic stem cell transplantation (AHST). We examined the use of IL-2 and growth factors for mobilization, ex vivo activation of peripheral blood stem cell (PBSC) and maintenance therapy after HDC/AHST in metastatic breast cancer. Eligible patients with metastatic breast cancer for HDC/AHST were assigned to 1 of 3 protocols for PBSC mobilization: G-CSF (group 1); IL-2 + G-CSF (group 2); or IL-2 + G-CSF + GM-CSF (group 3). HDC with cyclophosphamide, carmustine and thiotepa was given from day -7 to -5. PBSCs were treated ex vivo with IL-2 for 24 h and reinfused on day 0. Maintenance therapy included low-dose IL-2, followed by 2 courses of intermediate-dose IL-2. GM-CSF was given from day 1 until neutrophil recovery. Thirty-four patients (10 in group 1, 14 in group 2, and 10 in group 3) were included. Comparable numbers of CD34(+) cells were collected from all 3 groups; incremental increases of CD3(+) cells were collected from groups 1 to 2 and to 3 (p = 0.03). Major adverse effects from IL-2 were fever, hypotension and fatigue; no treatment-related mortality was seen. At a median follow-up of 790.5 days (range 150-2,722 days), median progression-free survival was 434 days and median overall survival was 1,432 days. Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates.
|
Authors | Yee Chung Cheng, Gabriela Rondón, Leah F Sanchez, John D McMannis, Daniel R Couriel, Marcos J de Lima, Chitra Hosing, Issa F Khouri, Sergio A Giralt, Richard E Champlin, Naoto T Ueno |
Journal | International journal of hematology
(Int J Hematol)
Vol. 90
Issue 5
Pg. 627-634
(Dec 2009)
ISSN: 1865-3774 [Electronic] Japan |
PMID | 19998065
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Interleukin-2
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(mortality, pathology, therapy)
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(administration & dosage, therapeutic use)
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Immunomodulation
- Interleukin-2
(administration & dosage, therapeutic use)
- Middle Aged
- Neoplasm Metastasis
- Survival Rate
- Transplantation, Autologous
- Treatment Outcome
- Young Adult
|